General MedicationsORALStandard

WIDAPLIK

AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN

Standard Dose

EQ 5MG BASE;2.5MG;40MG

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Prescription

Summary

Approval overview WIDAPLIK is listed in Drugs@FDA under application 219423 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN Form and strength TABLET;ORAL - EQ 5MG BASE;2.5MG;40MG Sponsor AZURITY Submission history Latest submission status date: 2025-06-05 00:00:00.

Structured Monograph

Clinical summary

Approval overview WIDAPLIK is listed in Drugs@FDA under application 219423 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN Form and strength TABLET;ORAL - EQ 5MG BASE;2.5MG;40MG Sponsor AZURITY Submission history Latest submission status date: 2025-06-05 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: Prescription
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.